journal article·2022-03-02Open access

Nanoemulsion-Assisted siRNA Delivery to Modulate the Nervous Tumor Microenvironment in the Treatment of Pancreatic Cancer

Ling Ding, Siyuan Tang, Ao Yu, Anlin Wang, Weimin Tang, Huizhen Jia, David Oupický

Abstract

Pancreatic cancer (PC) is a fatal human cancer, whose progression is highly dependent on the nervous tumor microenvironment. In the present study, cationic perfluorocarbon nanoemulsions were employed as an intraperitoneal delivery platform to facilitate the delivery and penetration of a therapeutic small interfering RNA (siRNA) to orthotopic pancreatic tumors. The nanoemulsion was used to silence the expression of the nerve growth factor (NGF) as a way of favorably modulating the tumor–neuronal interactions in pancreatic tumors. The nanoemulsions exhibited deep tumor penetration that was dependent on exocytosis and enhanced NGF gene silencing in vitro and in vivo when compared with control polycation/siRNA polyplexes, leading to the effective and safe suppression of tumor growth in orthotopic PC. Overall, emulsion-assisted delivery of NGF siRNA is a promising treatment approach for PC by targeting the interactions between the tumor cells and the nervous microenvironment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · MicroRNA in disease regulation · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA

Funding

National Cancer Institute · University of Nebraska Medical Center · State of Nebraska

References (46)

Show source-provided references
1. 10.14740/wjon116610.14740/wjon1166 ↗
2. 10.3390/ijms1807133810.3390/ijms18071338 ↗
3. 10.3389/fcell.2020.60173810.3389/fcell.2020.601738 ↗
4. 10.1038/s41392-020-0205-z10.1038/s41392-020-0205-z ↗
5. 10.1016/j.jbior.2014.11.00310.1016/j.jbior.2014.11.003 ↗
6. 10.3390/cancers301051010.3390/cancers3010510 ↗
7. 10.1046/j.1471-4159.2003.02178.x10.1046/j.1471-4159.2003.02178.x ↗
8. 10.1038/ncomms1513010.1038/ncomms15130 ↗
9. Zhu Z. W. · Clin. Cancer Res. · 2001 · 7 · 105
10. 10.1016/j.cell.2020.10.01610.1016/j.cell.2020.10.016 ↗
11. 10.1021/acsnano.9b0397810.1021/acsnano.9b03978 ↗
12. 10.3892/ol.2017.751210.3892/ol.2017.7512 ↗
13. 10.1007/s10555-010-9256-x10.1007/s10555-010-9256-x ↗
14. 10.2217/fon.10.10010.2217/fon.10.100 ↗
15. 10.2217/nnm.12.20310.2217/nnm.12.203 ↗
16. 10.1016/j.biomaterials.2014.03.04710.1016/j.biomaterials.2014.03.047 ↗
17. 10.20892/j.issn.2095-3941.2021.015810.20892/j.issn.2095-3941.2021.0158 ↗
18. 10.1016/j.colsurfb.2016.07.03310.1016/j.colsurfb.2016.07.033 ↗
19. 10.1021/acsami.5b0422610.1021/acsami.5b04226 ↗
20. 10.1016/j.bbamem.2011.11.02010.1016/j.bbamem.2011.11.020 ↗
21. 10.1073/pnas.063176610010.1073/pnas.0631766100 ↗
22. 10.1074/jbc.M01049920010.1074/jbc.M010499200 ↗
23. 10.3390/cancers301051010.3390/cancers3010510 ↗
24. 10.1158/1078-0432.Ccr-09-232910.1158/1078-0432.Ccr-09-2329 ↗
25. 10.1038/leu.2017.8210.1038/leu.2017.82 ↗
26. 10.1158/1078-0432.Ccr-09-238410.1158/1078-0432.Ccr-09-2384 ↗
27. 10.1371/journal.pone.008058010.1371/journal.pone.0080580 ↗
28. 10.1016/j.addr.2016.07.00110.1016/j.addr.2016.07.001 ↗
29. 10.1002/adfm.20160390710.1002/adfm.201603907 ↗
30. 10.1038/labinvest.2017.12710.1038/labinvest.2017.127 ↗
31. 10.1016/j.biomaterials.2019.11974210.1016/j.biomaterials.2019.119742 ↗
32. 10.2147/ijn.s16490510.2147/ijn.s164905 ↗
33. 10.4103/0975-8453.5950910.4103/0975-8453.59509 ↗
34. 10.18632/oncotarget.2774510.18632/oncotarget.27745 ↗
35. 10.1152/ajprenal.00313.200410.1152/ajprenal.00313.2004 ↗
36. 10.1038/sj.gt.330143510.1038/sj.gt.3301435 ↗
37. 10.1002/cbin.1045910.1002/cbin.10459 ↗
38. 10.1016/j.jconrel.2021.03.02810.1016/j.jconrel.2021.03.028 ↗
39. 10.1002/adhm.20170101910.1002/adhm.201701019 ↗
40. 10.1016/j.cis.2013.10.01310.1016/j.cis.2013.10.013 ↗
41. 10.1039/c6cs00636a10.1039/c6cs00636a ↗
42. 10.3390/genes1101000610.3390/genes11010006 ↗
43. Tezel E. · Clin. Cancer Res. · 2000 · 6 · 4764
44. 10.1016/j.molonc.2015.05.00110.1016/j.molonc.2015.05.001 ↗
45. 10.1038/s41388-020-01578-410.1038/s41388-020-01578-4 ↗
46. 10.18632/oncotarget.306910.18632/oncotarget.3069 ↗